Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- Wall St futures muted as oil tops $100 for first time since July
- Oil nears $100 as fresh Middle East strikes raise supply risks
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Eagle Pharmaceuticals (EGRX) Tops Q4 EPS by 66c, Sales Miss
March 1, 2017 6:52 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $3.52, $0.66 better than the analyst estimate of $2.86. Revenue for the quarter came in at $81.1 million versus the consensus estimate of $86.13 million.
Total revenue for the fourth quarter of 2016 grew 346% to $81.1 million;Product sales increased to $9.1 million compared to $2.9 million in Q4... More